Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
Brian B GodmanMagdalene WladysiukStuart McTaggartAmanj Baker KurdiEleonora AllocatiMihajlo Michael JakovljevicFrancis KalemeeraIris HoxhaAnna NachtnebelRobert SauermannManfred HintereggerVanda Marković-PekovićBiljana TubicGuenka PetrovaKonstantin TachkovJuraj SlabýRadka NejezchlebovaIva Selke KrulichováOtt LaiusGisbert W SelkeIrene LangnerAndrás HarsanyiAndrás InotaiArianit JakupiSvens HenkuzensKristina GaruolienėJolanta GulbinovičPatricia Vella BonannoJakub RutkowskiSkule IngebergØyvind MelienIleana MardareJurij FürstSean MacBride-StewartCarol HolmesCaridad PontesCorinne Zara YahniMarta Turu PedrolaMikael HoffmannVasileios KourafalosAlice PisanaRita BanziStephen CampbellBjörn WettermarkPublished in: BioMed research international (2021)
There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. This can be addressed.